Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095 29/10/2025

65,26 USD (-0,21%)

(-0,21%) 29/10/2025

Grafiek Halozyme Therapeutics Inc.

Grafiek Halozyme Therapeutics Inc.

1 dag1d -0,21%
1 week1w -1,35%
1 maand1m -11,02%
3 maanden3m 8,82%
6 maanden6m 6,25%
1 jaar1j 29,05%
5 jaar5j 129,79%

maandag 3 november 2025, 22:00

Kwartaalcijfers (3de kwartaal)

Halozyme Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

21 oktober 2025 · Halozyme to Report Third Quarter 2025 Financial and Operating Results · Persbericht

1 oktober 2025 · Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s · Persbericht

28 augustus 2025 · Halozyme to Participate at Upcoming Investor Conferences · Persbericht

5 augustus 2025 · Halozyme Raises 2025 Financial Guidance Ranges And Reports Strong Second Quarter 2025 Results · Persbericht

23 juli 2025 · European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma · Persbericht

22 juli 2025 · Halozyme to Report Second Quarter 2025 Financial and Operating Results · Persbericht

30 juni 2025 · Halozyme Therapeutics Added to Russell 1000® Index · Persbericht

20 juni 2025 · Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Persbericht

28 mei 2025 · Halozyme to Participate at Upcoming Investor Conferences · Persbericht

28 mei 2025 · Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications · Persbericht

Profiel Halozyme Therapeutics Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.halozyme.com

Hoofdzetel: San Diego, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe